Literature DB >> 6835318

Jejunoileal bypass for morbid obesity. Late follow-up in 100 cases.

M P Hocking, M C Duerson, J P O'Leary, E R Woodward.   

Abstract

To evaluate the results of jejunoileal bypass for morbid obesity, we studied 100 patients with intact bypasses an average of more than five years after surgery. Mean weight loss at five years was 102.7 lb (46.6 kg) (33 per cent). Although nearly half the patients regained some weight between one and five years after surgery, only 17 per cent regained 20 lb (9 kg) or more. Medical benefits (such as improved glucose tolerance and lowered blood pressure) were maintained at five years, but side effects and complications continued to occur in the late postoperative period. Diarrhea (more than three stools per day) persisted in 58 per cent of the patients, and electrolyte disturbances occurred in over a third. Diminished levels of B12 or folate or both were present in 88 per cent. Twenty-one per cent of the patients had nephrolithiasis, and 20 per cent of those who were at risk required cholecystectomy. Progressive hepatic structural abnormalities occurred in 29 per cent of the patients, and there was a 7 per cent incidence of cirrhosis. Although 81 per cent of the patients had satisfactory results at five years, side effects and complications continued to occur, mandating careful follow-up indefinitely. The risk-to-benefit ratio at five years after surgery seems acceptable, but the continued untoward effects of the bypass in the late postoperative period have led us to abandon this procedure in favor of gastric bypass. Only continued longitudinal follow-up will determine whether on balance jejunoileal bypass represents such a serious long-term health hazard that prophylactic restoration of intestinal continuity is indicated.

Entities:  

Mesh:

Year:  1983        PMID: 6835318     DOI: 10.1056/NEJM198304283081703

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  36 in total

1.  Treatment for morbid obesity.

Authors:  A R Carmichael
Journal:  Postgrad Med J       Date:  1999-01       Impact factor: 2.401

Review 2.  Imaging in bariatric surgery: service set-up, post-operative anatomy and complications.

Authors:  S Shah; V Shah; A R Ahmed; D M Blunt
Journal:  Br J Radiol       Date:  2010-11-02       Impact factor: 3.039

Review 3.  Bariatric surgery for obesity and metabolic disorders: state of the art.

Authors:  Ninh T Nguyen; J Esteban Varela
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-11-30       Impact factor: 46.802

Review 4.  Management strategies for weight control. Eating, exercise and behaviour.

Authors:  I D Caterson
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 5.  Biological effects of bariatric surgery on obesity-related comorbidities.

Authors:  Sabrena F Noria; Teodor Grantcharov
Journal:  Can J Surg       Date:  2013-02       Impact factor: 2.089

6.  Urinary evaluation after RYGBP: a lithogenic profile with early postoperative increase in the incidence of urolithiasis.

Authors:  Antonio Carlos Valezi; Paulo Emilio Fuganti; Jorge Mali Junior; Vinicius Daher Delfino
Journal:  Obes Surg       Date:  2013-10       Impact factor: 4.129

Review 7.  Biliopancreatic diversion in the surgical treatment of morbid obesity.

Authors:  Robrecht H G G Van Hee
Journal:  World J Surg       Date:  2004-04-19       Impact factor: 3.352

8.  Long-term consequences after jejunoileal bypass for morbid obesity.

Authors:  M P Hocking; G L Davis; D A Franzini; E R Woodward
Journal:  Dig Dis Sci       Date:  1998-11       Impact factor: 3.199

9.  Hemodynamic dysfunction in obesity hypoventilation syndrome and the effects of treatment with surgically induced weight loss.

Authors:  H J Sugerman; P L Baron; R P Fairman; C R Evans; G W Vetrovec
Journal:  Ann Surg       Date:  1988-05       Impact factor: 12.969

10.  Bariatric surgery for extreme adolescent obesity: indications, outcomes, and physiologic effects on the gut-brain axis.

Authors:  Stavra A Xanthakos
Journal:  Pathophysiology       Date:  2008-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.